At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 10, 2026 at 07:31 ET
SAB Biotherapeutics released Phase 1 data for its investigational therapy SAB-142 in established type 1 diabetes (T1D), showing early signals of C-peptide preservation, a marker of endogenous insulin production, in treated patients compared to placebo. While the cohort was small (n=6) and results are exploratory, the data support the drug's biological mechanism and provide momentum ahead of the ongoing Phase 2b SAFEGUARD trial in new-onset T1D, with topline results expected in 2H 2027.
- Phase 1 T1D cohort included 6 adult patients: 4 received SAB-142 (2.5 mg/kg), 2 received placebo.
- SAB-142-treated patients (n=4) showed no decrease in C-peptide at Day 120 vs. baseline; mean levels were preserved or increased.
- One placebo patient showed a decline in C-peptide consistent with expected disease progression; the second placebo patient discontinued early.
- Data align with SAB-142’s mechanism of action and prior biomarker evidence of T-cell modulation.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access